Raptor Pharmaceutical Corp. (RPTP) - NASDAQ
  • Wed, Apr. 6, 5:36 PM
    | Wed, Apr. 6, 5:36 PM | 3 Comments
  • Wed, Apr. 6, 1:45 PM
    | Wed, Apr. 6, 1:45 PM | 19 Comments
  • Thu, Feb. 25, 4:54 PM
    • Raptor Pharmaceutical (NASDAQ:RPTP): Q4 EPS of -$0.17 beats by $0.01.
    • Revenue of $24.7M (+42.9% Y/Y) misses by $1.38M.
    • Shares +1.8%.
    • Press Release
    | Thu, Feb. 25, 4:54 PM
  • Wed, Jan. 20, 5:39 PM
    • Top gainers, as of 5.25 p.m.: RYI +20.6%. CNXR +16.7%. PTX +11.1%. CPLP +9.9%. FBP +8.1%.
    • Top losers, as of 5.25p.m.: RPTP -12.4%. UDF -10.7%. LIOX -8.9%. NLNK -8.7%. RELY -7.7%.
    | Wed, Jan. 20, 5:39 PM | 2 Comments
  • Nov. 16, 2015, 8:51 AM
    • Raptor Pharmaceuticals (NASDAQ:RPTP) is down 15% premarket on light volume in response to its announcement of additional data from its CyNCh study assessing lead product candidate RP103 for the treatment of children with moderate-to-severe nonalcoholic fatty liver disease (NAFLD). The results will be presented today at The Liver Meeting in San Francisco.
    • As previously reported on September 14, there was no statistically valid difference in response rate between the RP103 cohort and placebo (28% vs. 22%; p=0.34). No statistically significant difference was observed in the components of the NAS score or fibrosis, but an improvement in the number of subjects with lobular inflammation was seen (36% vs. 21%), although this also fell short of statistical significance when adjusted for multiple comparisons.
    • A post-hoc analysis showed a statistically significant difference in the primary endpoint of improvement in liver histology versus placebo in patients weighing no more than 65 kg (p=0.01), about 28% of the study population. No improvement in liver histology was seen in subjects weighing more than 65 kg.
    • Statistically significant improvements compared to placebo in the liver enzymes ALT, AST and GGT (p=0.02, p=0.008 and p=0.02, respectively) from baseline to week 52 were also seen.
    • Raptor has yet to recover from its plunge in September in response to its initial report of results from CyNCh. Shares are still down over 60% from early summer.
    | Nov. 16, 2015, 8:51 AM
  • Sep. 14, 2015, 12:45 PM
    | Sep. 14, 2015, 12:45 PM | 6 Comments
  • Sep. 14, 2015, 9:14 AM
    | Sep. 14, 2015, 9:14 AM
  • Sep. 14, 2015, 7:43 AM
    • Raptor Pharmaceutical (NASDAQ:RPTP) reports that its product candidate for the treatment of nonalcoholic steatohepatitis (NASH) in adolescents aged 8 - 17, RP103 (cysteamine bitartrate), failed to achieve its primary endpoint of a two point decrease in NAFLD Activity Score (NAS) and no worsening of fibrosis compared to placebo (p=0.34) in a Phase 2b study.
    • The trial, called CyNCh, assessed RP103 in 169 children. Subjects were randomized to receive either 600 mg/day, 750 mg/day, 900 mg/day of RP103 or placebo for 52 weeks.
    • The results will be submitted for publication and presented at the American Association for the Study of Liver Diseases meeting in November in San Francisco, CA.
    • Based on the results, the company will cease development of RP103 for NASH. Its development for Huntington's disease and mitochondrial diseases in ongoing.
    • Shares are off 36% premarket on robust volume.
    | Sep. 14, 2015, 7:43 AM | 2 Comments
  • Jun. 10, 2015, 5:38 PM
    | Jun. 10, 2015, 5:38 PM | 6 Comments
  • Mar. 24, 2015, 5:35 PM
    • Top gainers, as of 5:15 p.m.: KFX +45.3%. LXK +10.3%. ARNA +3.9%. RPTP +3.7%. CLDN +2.7%.
    • Top losers, as of 5:15 p.m.: CBK -7.2%. ENLK -5.7%. ENOC -4.6%. NSM -4.6%. TGS -3.9%.
    | Mar. 24, 2015, 5:35 PM
  • Jan. 7, 2015, 8:50 AM
    • Thinly-traded nano cap Galectin Therapeutics (NASDAQ:GALT) is up 49% premarket on robust volume in response to its report of results from a 30-patient Phase 1 study of GR-MD-02 in patients with nonalcoholic steatohepatitis (NASH).
    • The principal objective of the trial was to assess the safety, tolerability and pharmacokinetics of GR-MD-02 but investigators also noted a potential therapeutic effect on fibrosis as measured by a serum biomarker (FibroTest) and liver stiffness (FibroScan). Patients in cohort 3 who received 8 mg/kg GR-MD-02 showed a statistically significant reduction in FibroTest score versus placebo in one of the cohorts.
    • Fibrotest is a composite score of six blood tests that correlate to the extent of liver fibrosis.
    • NASH represents the next big potential payoff for drug firms after HCV.
    • Previously: Galectin NASH treatment meets primary endpoint in Phase 1 (Nov. 10, 2014)
    • NASH-associated tickers: (NASDAQ:GILD) (NASDAQ:SHPG) (NASDAQ:LJPC) (NASDAQ:CNAT) (NASDAQ:ICPT) (NASDAQ:RPTP)
    | Jan. 7, 2015, 8:50 AM | 1 Comment
  • Aug. 8, 2014, 3:49 PM
    • First the good news:
    • Tekmira (TKMR +38.1%) on a massive 25M share turnover; Raptor Pharmaceuticals (RPTP +28.2%) on a 4x surge in volume; Clovis Oncology (CLVS +11.6%) on 50% higher volume; RadNet (RDNT +20.4%) on 2x higher volume and Relypsa (RLYP +15%) on 2x higher volume.
    • Now the bad news:
    • TearLab (TEAR -21.2%) on 4x higher volume; Masimo (MASI -10.6%) on 3x higher volume; Volcano (VOLC -19.9%) on a 12x surge in volume and Hanger (HGR -24.9%) on a 16x surge in volume.
    | Aug. 8, 2014, 3:49 PM | 1 Comment
  • Aug. 8, 2014, 12:47 PM
    | Aug. 8, 2014, 12:47 PM
  • Jun. 20, 2014, 5:36 PM
    | Jun. 20, 2014, 5:36 PM
  • Jun. 17, 2014, 5:35 PM
    | Jun. 17, 2014, 5:35 PM
  • Mar. 14, 2014, 12:48 PM
    | Mar. 14, 2014, 12:48 PM | 1 Comment
Company Description
Raptor Pharmaceutical Corp. is a biopharmaceutical company, which focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It has active development programs in cystinosis, a rare genetic disease, as well as other genetic and... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States